Clinical Trial Update: Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the immunogenicity and safety of PCV13 and Fluad in adults aged 60 years and older has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• FLUAD (influenza vaccine with MF59 adjuvant)
• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Korea University Guro Hospital | Conditions: Influenza, Streptococcus Pneumoniae | Phase 4 | Status: COMPLETED